

On-line Table: Comparisons of pre-existing^a CBV, CMRO₂, CBF, and OEF among MCA ROIs with abnormally increased RS, abnormally decreased RS, unchanged RS, and MCA ROIs in healthy subjects as controls

	A		B		C		D		A vs B		A vs C		A vs D		B vs C		B vs D		C vs D	
	Controls (n = 20) (Mean)		Abnormally Increased RS ^b (n = 22) (Mean)		Abnormally Decreased RS ^c (n = 47) (Mean)		Unchanged RS ^d (n = 28) (Mean)		(P Value)		(P Value)		(P Value)		(P Value)		(P Value)		(P Value)	
CBV (mL/100 g)	3.74 ± 0.59		5.19 ± 0.35		3.39 ± 0.67		3.49 ± 0.75		<.0001 ^e		.0653		.2768		<.0001 ^e		<.0001 ^e		.5689	
CMRO ₂ (mL/100 g/min)	3.49 ± 0.59		3.25 ± 0.27		2.96 ± 0.44		2.71 ± 0.50		.1511		.0015 ^e		<.0001 ^e		.0155 ^e		.0002 ^e		.0248 ^e	
CBF (mL/100 g/min)	47.17 ± 4.78		36.39 ± 3.25		41.64 ± 4.67		35.72 ± 4.71		<.0001 ^e		.0157 ^e		<.0001 ^e		.0008 ^e		.3654		.0005 ^e	
OEF (%)	42.69 ± 4.37		51.53 ± 4.64		42.91 ± 3.26		43.77 ± 5.00		<.0001 ^e		.9290		.4029		<.0001 ^e		<.0001 ^e		.3518	

^a PET data in a resting state without acetazolamide challenge within 5 days before MR imaging studies.

^b RS after acetazolamide administration above the upper limit of the 95% confidence interval of RS without acetazolamide challenge.

^c RS after acetazolamide administration below the lower limit of the 95% confidence interval of RS without acetazolamide challenge.

^d RS after acetazolamide administration within the 95% confidence interval of RS without acetazolamide challenge.

^e Statistically significant after correction using the Holm method.